Thu, March 3, 2011
Wed, March 2, 2011
[ Wed, Mar 02nd 2011 ] - Market Wire
BURCON AMENDS LETTER OF INTENT
Tue, March 1, 2011
Mon, February 28, 2011
Sun, February 27, 2011
Fri, February 25, 2011
Thu, February 24, 2011
Wed, February 23, 2011
Tue, February 22, 2011
[ Tue, Feb 22nd 2011 ] - Market Wire
PROTOX APPOINTS NEW DIRECTORS
Mon, February 21, 2011
Sun, February 20, 2011
Fri, February 18, 2011
Thu, February 17, 2011
Wed, February 16, 2011
Tue, February 15, 2011

Ligand to Present at the Citi 2011 Global Healthcare Conference on March 2


//health-fitness.news-articles.net/content/2011/ .. 011-global-healthcare-conference-on-march-2.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


SAN DIEGO--([ BUSINESS WIRE ])--Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today that President and Chief Executive Officer John Higgins will present at the Citi 2011Global Healthcare Conference on Wednesday, March 2 at 10:00 a.m. Eastern time (7:00 a.m. Pacific). The conference takes place at the Hilton New York.

A live webcast of the presentation will be available on the Companya�s website [ www.ligand.com ]. A replay of the presentation will be archived on the site for 30 days.

About Ligand Pharmaceuticals

Ligand is a BioPharma company with a business model that is based upon the concept of developing or acquiring royalty revenue generating assets and coupling them to an efficiently lean corporate cost structure. Liganda�s goal is to produce a bottom line that supports a sustainably profitable business. By diversifying the portfolio of assets across numerous technology types, therapeutic areas, drug targets, and industry partners, we offer investors a de-risked opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. We believe Ligand has assembled one of the largest and most diversified portfolio of current assets in the industry for a company of its size, currently exceeding 60 programs, with the potential to generate revenue in the future. These therapies address the unmet medical needs of patients for a broad spectrum of diseases including hepatitis, muscle wasting, Alzheimer's disease, dyslipidemia, diabetes, anemia, COPD, asthma, rheumatoid arthritis, osteoporosis and cancer. Ligand has established multiple alliances with the world's leading pharmaceutical companies including GlaxoSmithKline, Merck, Pfizer, Bristol-Myers Squibb and AstraZeneca. For more information, please visit [ www.ligand.com ].


Publication Contributing Sources